For twenty years Intuitive Surgical had no credible competitor in soft-tissue robotics. In eight months it acquired two — Medtronic's Hugo in December, J&J's Ottava in July. Meanwhile revenue still grew 19% and non-GAAP earnings 28%, and the stock lost a third of its value. Five analyst lenses, three scenarios, four horizons.
Gray line = ISRG's actual monthly closes from mid-2024 into today — a run from $444.85 (Jun ’24) to a $573.48 monthly-close peak in Nov ’25, then seven consecutive down months to a $353.33 July close and a $328.57 intraday low, before August's bounce to $378.81. Colored paths right of the TODAY crosshair are synthesized scenario midpoints, weighted base 50% · bull 25% · bear 25%. Mid-year marks. The clay circle is Wall Street's 12-month consensus of $478.01 (range $324–$685, 33 analysts, S&P Global, Aug 2026).
Those probabilities are this desk's judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of every scenario card update live.
Each lens below was run independently, with the same ground-truth data and no sight of the others, so the disagreement is real rather than staged. Targets span $311 to $500 — a 61% spread on identical facts.
Procedures (+16%) are out-running the installed base (+12%) — utilization per system is rising, and ~85% of revenue repeats without a new capital sale. 246 of 468 placements were da Vinci 5 against a ~7-year upgrade cadence, and August's cardiac clearance takes ~17,000 procedures toward a ~160,000/yr addressable pool. Non-GAAP EPS +28% on revenue +19% is nine points of operating leverage already printing.
FCF more than doubled to $3.22B as capex rolled from $1,111M (FY24) to $484M TTM — but capex intensity fell from 13.3% of revenue to 4.4%, which is a trough, not a run-rate. Normalize it and the yield is ~2.2%. Net cash of ~$8.5B ($24.43/share) funds a price war; it does not set a floor. At 39.9× EV/FCF you are still underwriting flawless compounding.
U.S. procedures slowed +14% → +12% on causes that are structural, not transitory: GLP-1 penetration is still climbing and ACA subsidy expiry is a multi-year coverage drag. Guidance was reaffirmed, not raised — H2 must decelerate. China is the preview of an open market: domestic brands took ~48% of 2025 unit procurement and average system prices fell ~25% in H1’26. The 66–67% gross margin was set with nobody bidding on the other side.
Ottava and Hugo breach the placement monopoly, not the procedure monopoly. A hospital that buys Ottava does not un-buy da Vinci — it becomes a two-platform hospital, and the credentialed surgeons stay. Erosion runs in sequence: system ASP in greenfield and international first, incremental placement share second, instrument pricing last and slowest. Instruments (+18% on $1.73B/qtr) are the profit pool, and they are furthest from the fire.
Seven consecutive down months (Jan–Jul ’26), a death cross confirmed in March, price 18.9% below its 12-month moving average of $466.85. The +15.3% bounce off $328.57 sits squarely in the bear-rally band and has not reclaimed June's $397.68 close. Valuation says bottom-decile — 33.5× forward against a 5-year average near 69×; the tape says not yet. Beta 1.46 with zero debt is pure duration, and duration unwinds slowly.
Bars sorted low to high, colored by rating; the dashed line is today's $378.81. Note the shape of the disagreement — one desk below the price, one at nearly double it.
Named targets are dated actions from July–August 2026: Oppenheimer upgraded to Outperform at $500 (Aug 12); HSBC downgraded to Hold at $391 (Jul 30); JPMorgan, Stifel and Citigroup all cut targets on Jul 17, the day after Q2. The unnamed endpoints are the extremes of the S&P Global range ($324 low, $685 high) — the firms behind them are not disclosed in the source. Rating distribution: 16 Strong Buy · 7 Buy · 9 Hold · 1 Strong Sell. MarketBeat's tally of 31 analysts puts the consensus higher at $508.68, so the true consensus sits somewhere in the $478–$509 band; this report uses the S&P Global figure as the primary.
Synthesized scenario midpoints, dated mid-year, shown against today's $378.81. Every number below is an EPS estimate times an exit multiple — the math is in the drawers underneath. These are illustrative frameworks, not forecasts; real outcomes can and do fall outside the cone.
The single most underrated chart in this report. Capex peaked in 2024 and halved; free cash flow more than tripled behind it — and the debt bar is barely visible at all.
The bull and bear cases both live in the gap between the clay bar and the olive one. Intuitive spent heavily on manufacturing capacity in 2023–24 (capex $1.06B then $1.11B, ~13% of revenue), then stopped — FY25 capex was $540M and the trailing-twelve-month figure through June 2026 is $484M, about 4.4% of revenue. Operating cash flow rose to $3.71B over the same stretch, so free cash flow went $750M → $1,304M → $2,491M → $3,223M TTM. The value lens's caution is that 4.4% is a trough, not a run-rate; normalize capex toward 7% of revenue and FY26 free cash flow is nearer $2.9B. Total debt (slate) is a rounding error — $171M at FY25 against $8.63B of cash and investments, so the $3.96B of trailing buybacks is funded entirely from cash. FY2026E revenue is the $11.77B analyst consensus; FY2026E capex and FCF are this desk's estimates extrapolated from the TTM run-rate and are not company guidance.
No price target here is a guess — each is one of these bars times an exit multiple. This is the ladder.
Read the basis change carefully. Gray bars are reported GAAP diluted EPS: $3.65 (FY22) → $5.03 → $6.42 → $7.87 (FY25). Olive bars are non-GAAP estimates — FY2026E is the $10.79 analyst consensus, FY2027–31E is this desk's base-case ladder (+17% / +15% / +14% / +13% / +13%). The two measures differ mainly by stock-based compensation: FY25 was $7.87 GAAP versus $8.93 non-GAAP, so roughly $1.06 of the visible step from 2025 to 2026 is the change in basis rather than growth. Trailing GAAP EPS through June 2026 was $8.72. Base case: $21.13 of FY31E non-GAAP EPS × a 30× exit multiple ≈ the $634 five-year base-case price.
Q2 FY2026, year-over-year. Read these against a stock that has fallen 37% from its high — and read the top bar against all the others.
Ten metrics, nine of them positive. Total revenue +19%, instruments and accessories +18%, non-GAAP EPS +28%, with SP (+61%), Ion procedures (+36%) and the Ion installed base (+21%) compounding far faster off small bases (clay). The single terracotta bar is the one the bears point at: U.S. bariatric procedure volumes fell by a high-single-digit percentage as GLP-1 drugs displaced surgery — and the U.S. da Vinci line, at +12%, is the slowest growth on the board and decelerating from +14% in Q1. That is the whole debate in one chart: the frontier is fine, the core is fine, and the marginal U.S. case is not.
The entire valuation argument compresses into one disagreement: does an installed base of 11,710 systems and two decades of surgeon training constitute a moat, or merely a head start?
Where each risk sits, not just how large it is, over a three-to-five year horizon. Grid labels are shortened; the cards beneath name each risk in full. The hot upper-right corner is the one that decides the stock; note that the competitive risks everyone talks about sit one row down.
What breaks: procedures are the annuity — instruments and service both bill per case. Low-teens is what the whole model and every target on this page assume.
What breaks: Intuitive stops winning the marginal operating room. System ASP compresses first in greenfield, ASC and international accounts where no surgeon is yet credentialed.
What breaks: the actual profit pool. If Medtronic bundles Hugo consumables across its surgical portfolio, the $1.73B-a-quarter razor-blade line becomes a negotiated price rather than a posted one.
What breaks: a serious adverse-event cluster or FDA action against robotic soft-tissue surgery as a category would hit the installed base, not just new sales — low odds, but it reprices everything overnight.
What breaks: a whole procedure category quietly leaves the operating room. U.S. bariatric volumes are already down high-single-digits and GLP-1 penetration is still climbing.
What breaks: the template. Domestic competitors plus national pricing pressure show what an open, tendered market does to system ASPs — the question is whether it stays contained to China.
What breaks: roughly a point of gross margin. Already embedded in the 68–69% FY26 guide, plus higher freight and semiconductor costs flagged for the second half.
What breaks: the upgrade cycle stalls. With ~half of U.S. dV5 placements being trade-ins, a field action would pause the single largest driver of system revenue.
What breaks: reported growth optics. Ex-U.S. is now the faster half (+20%), so currency and country-level reimbursement decisions swing the headline more than they used to.
What breaks: continuity of a famously long-horizon capital allocator — disruptive at the margin, but the installed base does not care who signs the letter.
Hover the dotted terms anywhere in this report, or scan the desk's working definitions here.